Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

Baricitinib is the first once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of moderate to severe active rheumatoid arthritis (RA).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news